Natus Medical (NTUS) 10-Q 7 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	5-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'NATUS MEDICAL INC	'
Entity Central Index Key	'0000878526	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	32,142,534

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$59,589	$56,106
Accounts receivable, net of allowance for doubtful accounts of $3,618 in 2014 and $2,962 in 2013	79,933	82,110
Inventories	35,455	37,685
Prepaid expenses and other current assets	14,218	11,904
Deferred income tax	9,055	8,956
Total current assets	198,250	196,761
Property and equipment, net	21,530	23,295
Intangible assets	98,141	98,820
Goodwill	100,929	97,238
Other assets	10,441	10,324
Total assets	429,291	426,438
Current liabilities:	'	'
Accounts payable	26,057	29,777
Current portion of long-term debt	10,437	10,517
Accrued liabilities	25,750	26,831
Deferred revenue	11,775	12,946
Total current liabilities	74,019	80,071
Long-term liabilities:	'	'
Long-term debt, net of current portion	22,500	27,500
Other liabilities	3,207	2,845
Deferred income tax	9,748	9,704
Total liabilities	109,474	120,120
Stockholders' equity:	'	'
Common Stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding 32,102,547 in 2014 and 31,401,602 in 2013	302,109	292,055
Retained earnings	40,767	34,516
Accumulated other comprehensive loss	-23,059	-20,253
Total stockholders' equity	319,817	306,318
Total liabilities and stockholders' equity	$429,291	$426,438

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts	$3,618	$2,962
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	120,000,000	120,000,000
Common Stock, shares issued	32,102,547	31,401,602
Common Stock, shares outstanding	32,102,547	31,401,602

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) [Abstract]	'	'
Revenue	$85,624	$85,834
Cost of revenue	35,733	36,601
Gross profit	49,891	49,233
Operating expenses:	'	'
Marketing and selling	21,422	22,196
Research and development	7,508	8,212
General and administrative	12,280	13,966
Total operating expenses	41,210	44,374
Income from operations	8,681	4,859
Other income (expense), net	312	-334
Income before provision for income tax	8,993	4,525
Provision for income tax expense	2,742	1,083
Net income	6,251	3,442
Foreign currency translation adjustment	-2,891	-2,331
Comprehensive income	$3,360	$1,111
Earnings (loss) per share:	'	'
Basic	$0.20	$0.12
Diluted	$0.19	$0.11
Weighted average shares used in the calculation of earnings (loss) per share:	'	'
Basic	31,062	29,570
Diluted	32,185	30,319

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities:	'	'
Net income	$6,251	$3,442
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	3,302	3,133
Provision for losses on accounts receivable	465	372
Warranty reserve	390	656
Loss on disposal of property and equipment	'	6
Share-based compensation	1,609	1,360
Excess tax benefit on the exercise of stock options	-2,194	-81
Changes in operating assets and liabilities:	'	'
Accounts receivable	708	-787
Inventories	1,633	64
Prepaid expenses and other assets	-1,936	734
Accounts payable	-2,710	-3,302
Deferred income tax	1,844	-304
Accrued liabilities and deferred revenue	-3,678	-6,228
Net cash provided by (used in) operating activities	5,684	-935
Investing activities:	'	'
Acquisition of businesses, net of cash acquired	-4,925	-18,600
Purchases of property and equipment	-806	-687
Purchase of intangible assets	'	-669
Net cash used in investing activities	-5,766	-19,956
Financing activities:	'	'
Proceeds from stock option exercises and ESPP purchases	35	2,115
Excess tax benefit on the exercise of stock options	2,194	81
Proceeds from short-term borrowings	'	22,000
Payments on borrowings	-5,079	-2,142
Net cash provided by financing activities	3,415	22,054
Exchange rate changes effect on cash and cash equivalents	150	134
Net increase (decrease) in cash and cash equivalents	3,483	1,297
Cash and cash equivalents, beginning of period	56,106	23,057
Cash and cash equivalents, end of period	59,589	24,354
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	186	613
Cash paid for income taxes	574	4,214
Non-cash investing activities:	'	'
Property and equipment included in accounts payable	265	261
Inventory transferred to property and equipment	$398	'

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Basis of Presentation [Abstract]	'
Basis of Presentation	'
	1 - Basis of Presentation
	The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (“Natus,” “we,” “us,” “our,” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2013 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	Recent Accounting Pronouncements
	Recently issued FASB guidance and Securities and Exchange Commission (“SEC”) Staff Accounting Bulletins have either been implemented, with no significant effect, or are not applicable to the Company.

Business_Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	2 - Business Combinations
	Grass Technologies
	On February 2, 2013, we completed an asset purchase of the Grass Technologies Product Group (“Grass”) from Astro-Med Inc. for a total cash consideration of $21.0 million pursuant to purchase agreement. Included in the total cash consideration is an adjustment of $2.4 million made in the first quarter of 2014 for inventory purchase committments. Grass manufactures and sells clinically differentiated neurodiagnostic and monitoring products, including a portfolio of electroencephalography (EEG) and polysomnography (PSG) systems for both clinical and research use and related accessories and proprietary electrodes. The acquisition strengthened the Company’s existing neurology portfolio and provided new product categories. A total of $624,000 of direct costs associated with the acquisition was expensed as incurred and reported as a component of general and administrative expenses.
	The Company has accounted for the acquisition as a business combination. Under the acquisition method of accounting, the assets acquired and liabilities assumed from Grass are recorded in the consolidated financial statements at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets has been recorded as goodwill. Grass’s results of operations are included in our consolidated financial statements as of February 2, 2013, the date of the acquisition.
	Valuing certain components of the acquisition required us to make significant estimates. In the first quarter of 2014, the remaining information was obtained requiring adjustments to these estimates. The final adjustments in the first quarter of 2014 resulted in an adjustment to the preliminary purchase price allocation, with an offsetting adjustment to goodwill. These adjustments were deemed immaterial and as a result our financial statements were not adjusted retrospectively.
	Approximately $7.0 million has been allocated to goodwill. Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed and represent primarily the expected synergies of combining the operations of the Company and the Grass business. None of the goodwill is expected to be deductible for tax purposes. In accordance with ASC 350-20, goodwill will not be amortized but instead will be tested for impairment at least annually (more frequently if certain indicators are present).
	Pro forma financial information
	The following unaudited pro forma information combining results of operations of the Company for the three months ended March 31, 2014 and 2013 are presented as if the acquisition of Grass had occurred on January 1, 2013:
	Unaudited Pro forma Financial Information
	(in thousands)
		Three Months Ended March 31, 2013
	Revenue	$86,839
	Income from operations	$5,239
	The unaudited pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisitions occurred on the dates indicated, nor does it give effect to synergies, cost savings, and other changes expected to result from the acquisitions. Accordingly, the pro forma financial results do not purport to be indicative of results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period.
	For purposes of preparing the unaudited pro forma financial information for the period January 1, 2013 through March 31, 2013, Grass’ statement of operations for the period from January 1, 2013 to February 1, 2013 was combined with our consolidated statement of operations and comprehensive income (loss) for the three months ended March 31, 2013.
	The unaudited pro forma consolidated results for the three month period ended March 31, 2013 reflect the historical information of Natus and Grass, adjusted for the following pre-tax amounts:
	Additional amortization expense of $59,300 related to the fair value of identifiable intangible assets acquired;
	Decrease of depreciation expense of $14,800 related to the fair value adjustment to property and equipment acquired;
	Decrease in general and administrative expense of $624,000 related to the direct acquisition costs that were recorded in the unaudited pro forma financial information in the three months ended March 31, 2013.
	Hearing Screening as a Service
	In the first quarter of 2014, the company entered into two asset purchase agreements for companies in the newborn hearing screening services market for a total consideration of $3.6 million.  The first, Tender Touch Infant Hearing (“Tender Touch”), was acquired on January 16, 2014, and the second, Hearing Health Consultants LLC (“HHC”), was acquired on March 10, 2014.  Both acquisitions support the Company’s objective to enter this market that complements our hearing business.

Basic_and_Diluted_Earnings_Per

Basic and Diluted Earnings Per Common Share	3 Months Ended
	Mar. 31, 2014
Basic and Diluted Earnings Per Common Share [Abstract]	'
Basic and Diluted Earnings Per Common Share	'
	3 - Basic and Diluted Earnings Per Common Share
	Basic earnings per share is based upon the weighted average number of common shares outstanding during the period. Diluted earnings per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under our stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and unvested restricted stock are excluded from the computation when there is a loss as their effect is anti-dilutive or if the exercise price of such unexercised options is greater than the average market price of the stock for the period.
	For the three months ended March 31, 2014, common stock equivalents of 1,123,806 shares were included in the weighted average shares outstanding used to calculate diluted earnings per share, while common stock equivalents of 229,990 shares were excluded from the calculation of diluted earnings per share because the exercise price of the underlying options was greater than the average market price of the stock for the period.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Inventories	'
	4 - Inventories
	Inventories consist of the following (in thousands):
		31-Mar-14	31-Dec-13
	Raw materials and subassemblies	$21,381	$24,312
	Work in process	2,053	2,584
	Finished goods	19,731	17,861
	Total inventories	43,165	44,757
	Less: Non-current inventories	-7,710	-7,072
	Inventories, current	$35,455	$37,685
	At March 31, 2014 and December 31, 2013, the Company has classified $7.7 million and $7.1 million respectively, of inventories, as non-current other assets. This inventory consists primarily of service components used to repair products pursuant to warranty obligations and extended service contracts, including service components for products we are not currently selling. Management believes that these inventories will be utilized for their intended purpose.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2014
Intangible Assets / Goodwill [Abstract]	'
Intangible Assets	'
	5 – Intangible Assets
	The following table summarizes the components of gross and net intangible asset balances (in thousands):
			31-Mar-14								31-Dec-13
			Gross Carrying Amount		Accumulated Impairment	Accumulated Amortization			Net Book Value			Gross Carrying Amount	Accumulated Impairment	Accumulated Amortization			Net Book Value
	Intangible assets with definite lives:
	Technology			$65,746	--		($26,965)	)11		$38,781		$65,904	--		($25,519)	$40,385
	Customer related			32,278	--		-10,293			21,985		31,231	--		-9,763	21,468
	Internally developed software			11,917	--		-5,395			6,522		11,069	--		-5,107	5,962
	Patents			2,723	--		-2,121			602		2,724	--		-2,094	630
	Backlog			722	--		-722			--		722	--		-722	--
	Definite-lived intangible assets			113,386			-45,496			67,890		111,650	--		-43,205	68,445
	Intangible assets with indefinite lives:
	Tradenames			33,311	-3,060		--			30,251		33,435	-3,060		--	30,375
	Total Intangibles			$146,697	($3,060)		($45,496)			$98,141		$145,085	($3,060)		($43,205)	$98,820
	Definite-lived intangible assets are amortized over their weighted average lives of 15 years for technology, 12 years for customer related intangibles, 7 years for internally developed software, and 14 years for patents. Intangible assets with indefinite lives are not subject to amortization.
	Internally developed software consists of $10.4 million relating to costs incurred for development of internal use computer software and $1.5 million for development of software to be sold.
	Amortization expense related to intangible assets with definite lives was as follows (in thousands):
		Three Months Ended March 31,
		2014	2013
	Technology	$1,096	$963
	Customer Related	647	601
	Internally developed software	288	239
	Patents	30	20
	Total amortization	$2,061	$1,823
	Expected amortization expense related to amortizable intangible assets is as follows (in thousands):
	Nine months ending December 31, 2014	$		5,965
	2015			7,736
	2016			6,863
	2017			6,502
	2018			6,236
	2019			5,333
	Thereafter			29,255
	Total expected amortization expense	$		67,890

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2014
Intangible Assets / Goodwill [Abstract]	'
Goodwill	'
	6 – Goodwill
	The carrying amount of goodwill and the changes in those balances are as follows (in thousands):
	As of December 31, 2013	$97,238
	Acquisitions/Purchase Accounting Adjustments	4,001
	Foreign currency translation	-310
	As of March 31, 2014	$100,929

Property_and_Equipment_net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2014
Property and Equipment, net [Abstract]	'
Property and Equipment, net	'
	7 - Property and Equipment, net
	Property and equipment, net consist of the following (in thousands):
		31-Mar-14	31-Dec-13
	Land	$4,023	$4,152
	Buildings	9,490	10,269
	Leasehold improvements	2,795	2,789
	Office furniture and equipment	10,920	10,719
	Computer software and hardware	9,869	9,362
	Demonstration and loaned equipment	9,557	10,320
		46,654	47,611
	Accumulated depreciation and amortization	-25,124	-24,316
	Total	$21,530	$23,295
	Depreciation and amortization expense of property and equipment was approximately $1.2 million for the three months ended March 31, 2014, and was approximately $1.1 million for the three months ended March 31, 2013.

Reserve_for_Product_Warranties

Reserve for Product Warranties	3 Months Ended
	Mar. 31, 2014
Reserve for Product Warranties [Abstract]	'
Reserve for Product Warranties	'
	8 - Reserve for Product Warranties
	We provide a warranty on all medical device products that is generally one year in length. We also sell extended service agreements on our medical device products that are generally over one year in length. Service for domestic customers is provided by Company-owned service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of Company-owned facilities and vendors on a contract basis.
	We have accrued a warranty reserve, included in accrued liabilities on the accompanying balance sheets, for the expected future costs of servicing products during the initial warranty period. We base the liability on actual warranty costs incurred to service those products. On new products, additions to the reserve are based on a combination of factors including the percentage of service department labor applied to warranty repairs, as well as actual service department costs, and other judgments, such as the degree to which the product incorporates new technology. The reserve is reduced as costs are incurred to honor existing warranty obligations.
	The details of activity in the warranty reserve are as follows (in thousands):
		Three Months Ended March 31,
		2014	2013
	Balance, beginning of period	$3,143	$2,260
	Acquisition warranty assumed	--	191
	Warranty accrued for the period	390	656
	Repairs for the period	-522	-464
	Balance, end of period	$3,011	$2,643

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Share-Based Compensation	'
	9 - Share-Based Compensation
	At March 31, 2014, we have two active plans that give rise to share-based compensation, the 2011 Stock Awards Plan and the 2011 Employee Stock Purchase Plan. The terms of awards granted during the three months ended March 31, 2014 and our methods for determining grant-date fair value of the awards were consistent with those described in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Detail of share-based compensation expense is as follows (in thousands):
		Three Months Ended March 31,
		2014	2013
	Cost of revenue	$28	$59
	Marketing and sales	235	271
	Research and development	146	117
	General and administrative	1,199	913
	Total	$1,609	$1,360
	As of March 31, 2014, unrecognized compensation expense related to the unvested portion of our stock options and other stock awards was approximately $16.5 million, which is expected to be recognized over a weighted average period of 2.8 years.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	10 - Income Taxes
	Provision for Income Tax Expense
	We recorded provisions for income tax of $2.7 million and $1.1 million for the three months ended March 31, 2014 and 2013, respectively. Our effective tax rate was 30.5% and 23.9% for the three month period ended March 31, 2014 and 2013, respectively.
	Our effective tax rate for the three months ended March 31, 2014 differed from statutory tax rates primarily because of profits taxed in foreign jurisdictions with lower tax rates than the statutory rate.  Several temporary tax provisions including research and development tax credits and tax relief provisions to foreign income were expired on December 31 2013 as a part of the America Taxpayer Relief of 2012, which resulted in a higher effective tax rate for the three months ended March 31, 2014 compared with the effective tax rate for the three months ended ended March 31, 2013.
	Our effective tax rate for the three months ended March 31, 2013 differed from statutory tax rates primarily because of profits taxed in foreign jurisdictions with lower tax rates than the statutory rate and tax benefits of approximately $340,000 derived from the recognition of the 2012 federal research and development tax credit by enactment of the American Taxpayer Relief Act of 2012 in January 2013.
	We recorded a tax expense of $114,000 for new unrecognized tax benefits for the three months ended March 31, 2014. Included in the balance of unrecognized tax benefits on March 31, 2004 is $585,000 related to the tax position for which it is reasonably possible that the total amount could change during the next twelve months,
	Our tax returns remain open to examination as follows: U.S. Federal, 2010 through 2013, U.S. States 2009 through 2013 and significant foreign jurisdictions, 2009 through 2013.

Restructuring_Reserves

Restructuring Reserves	3 Months Ended
	Mar. 31, 2014
Restructuring Reserves [Abstract]	'
Restructuring Reserves	'
	11 - Restructuring Reserves
	The Company has historically incurred an ongoing level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization resulting from acquisitions.
	The balance of the restructuring reserve is included in accrued liabilities on the accompanying balance sheets. Employee termination benefits expensed are included as a part of general and administrative expenses.
	Activity in the restructuring reserves for the three months ended March 31, 2014 is as follows (in thousands):
	Balance at December 31, 2013	$	335
	Expensed		8
	Cash payments		-215
	Balance at March 31, 2014		128

Debt_and_Credit_Arrangements

Debt and Credit Arrangements	3 Months Ended
	Mar. 31, 2014
Debt and Credit Arrangements [Abstract]	'
Debt and Credit Arrangements	'
	12 - Debt and Credit Arrangements
	At March 31, 2014 the Company had a $75 million credit facility consisting of a $25 million revolving credit line and a $50 million 5-year term loan with Wells Fargo Bank, National Association (“Wells Fargo”). The $25 million credit line is fully available under the credit agreement. The credit facility contains covenants, including covenants relating to liquidity and other financial measurements, and provides for events of default, including failure to pay any interest when due, failure to perform or observe covenants, bankruptcy or insolvency events, and the occurrence of a material adverse effect, and restricts our ability to pay dividends. We are in compliance with all covenants as of March 31, 2014. We have granted Wells Fargo a security interest in substantially all of our assets. We have no other significant credit facilities.
	During the first quarter 2013 we borrowed $22 million under the credit facility principally to fund the Grass acquisition and to provide for other working capital needs. We had no additional borrowings..
	The credit facility was increased to $75 million in June 2013 and the term was extended to five years. As part of the amended credit facility in June 2013, we converted $31.2 million of short-term revolving debt to a term loan, increasing the term loan from $18.8 million as of March 31, 2013 to $50 million as of June 30, 2013.
	During the fourth quarter of 2013 and the first quarter of 2014 additional principal payments of $7.5 million and $5.0 million were made respectively. As a result of these additional principal payments the final payment on this term loan is scheduled to be made on or about June 30, 2017.
	Long-term debt is comprised of the following (2014 and 2013 columns in thousands):
		31-Mar-14	31-Dec-13
	Term loan $50 million, interest at LIBOR plus 1.75%, due September 30, 2018 with term loan principle repayable in quarterly installments of $2.5 million	$32,500	$37,500
	Term loan $2.9 million Canadian (“CAD”), interest at cost of funds plus 2.5%, due September 15, 2014 with principle repayable in monthly installments of $16,000 until August 15, 2014 and one final payment of $404,000 collateralized by a first lien on company owned land and building	437	517
	Total	32,937	38,017
	Less: current portion of long-term debt	-10,437	-10,517
	Total long-term debt	$22,500	$27,500
	Maturities of long-term debt as of March 31, 2014 are as follows (in thousands):
	Nine months ended December 31, 2014	$		7,937
	2015			10,000
	2016			10,000
	2017			5,000
	Total Total long-term debt	$		32,937
	At March 31, 2014 and December 31, 2013, the carrying value of total debt approximates fair market value. The fair value of the Company’s debt is considered a Level 2 measurement.

Segment_Customer_and_Geographi

Segment, Customer and Geographic Information	3 Months Ended
	Mar. 31, 2014
Segment, Customer and Geographic Information [Abstract]	'
Segment, Customer and Geographic Information	'
	13 - Segment, Customer and Geographic Information
	We operate in one reportable segment in which we provide healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments.
	Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors who resell our products to end users or sub‑distributors.
	Revenue and long-lived asset information is as follows (in thousands):
		Three Months Ended March 31,
		2014	2013
	Consolidated Revenue:
	United States	$48,346	$48,364
	Foreign countries	37,278	37,470
	Totals	$85,624	$85,834
		Three Months Ended March 31,
		2014	2013
	Revenue by End Market:
	Neurology Products
	Devices and Systems	$36,116	$34,707
	Supplies	14,226	15,447
	Services	6,144	5,553
	Total Neurology Revenue	56,486	55,707
	Newborn Care Products
	Devices and Systems	14,924	17,250
	Supplies	12,276	11,464
	Services	1,938	1,413
	Total Newborn Care Revenue	29,138	30,127
	Total Revenue	$85,624	$85,834
		31-Mar-14	31-Dec-13
	Property and equipment, net:
	United States	$9,265	$9,619
	Canada	5,868	6,060
	Argentina	3,941	4,932
	Other foreign countries	2,456	2,684
	Totals	$21,530	$23,295
	During the three months ended March 31, 2014 and 2013, no single customer or foreign country contributed to more than 10% of revenue.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	14 - Fair Value Measurements
	ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined under ASC 820 as the exit price associated with the sale of an asset or transfer of a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes the following three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:
	Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	The Company does not have any financial assets or liabilities measured at fair value on a recurring basis.
	The following financial instruments are not measured at fair value on the Company’s condensed consolidated balance sheet as of March 31, 2014 and December 31, 2013, but require disclosure of their fair values: cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt. Except for debt, the carrying value of these financial instruments approximates fair values because of their relatively short maturity.
	The carrying amount of the Company’s long term debt approximates fair value based on Level 2 inputs since the debt carries a variable interest rate that is tied to the current LIBOR rate plus a spread.

Business_Combinations_Tables

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Unaudited Pro forma Financial Information	'
		Three Months Ended March 31, 2013
	Revenue	$86,839
	Income from operations	$5,239

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventories [Abstract]	'
Summary of Inventories	'
		31-Mar-14	31-Dec-13
	Raw materials and subassemblies	$21,381	$24,312
	Work in process	2,053	2,584
	Finished goods	19,731	17,861
	Total inventories	43,165	44,757
	Less: Non-current inventories	-7,710	-7,072
	Inventories, current	$35,455	$37,685

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets / Goodwill [Abstract]	'
Components of gross and net intangible asset balances	'
			31-Mar-14								31-Dec-13
			Gross Carrying Amount		Accumulated Impairment	Accumulated Amortization			Net Book Value			Gross Carrying Amount	Accumulated Impairment	Accumulated Amortization			Net Book Value
	Intangible assets with definite lives:
	Technology			$65,746	--		($26,965)	)11		$38,781		$65,904	--		($25,519)	$40,385
	Customer related			32,278	--		-10,293			21,985		31,231	--		-9,763	21,468
	Internally developed software			11,917	--		-5,395			6,522		11,069	--		-5,107	5,962
	Patents			2,723	--		-2,121			602		2,724	--		-2,094	630
	Backlog			722	--		-722			--		722	--		-722	--
	Definite-lived intangible assets			113,386			-45,496			67,890		111,650	--		-43,205	68,445
	Intangible assets with indefinite lives:
	Tradenames			33,311	-3,060		--			30,251		33,435	-3,060		--	30,375
	Total Intangibles			$146,697	($3,060)		($45,496)			$98,141		$145,085	($3,060)		($43,205)	$98,820
Amortization expense related to intangible assets with definite lives	'
		Three Months Ended March 31,
		2014	2013
	Technology	$1,096	$963
	Customer Related	647	601
	Internally developed software	288	239
	Patents	30	20
	Total amortization	$2,061	$1,823
Expected amortization expense related to amortizable intangible assets	'
	Expected amortization expense related to amortizable intangible assets is as follows (in thousands):
	Nine months ending December 31, 2014	$		5,965
	2015			7,736
	2016			6,863
	2017			6,502
	2018			6,236
	2019			5,333
	Thereafter			29,255
	Total expected amortization expense	$		67,890

Goodwill_Tables

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets / Goodwill [Abstract]	'
Carrying amount of Goodwill	'
	As of December 31, 2013	$97,238
	Acquisitions/Purchase Accounting Adjustments	4,001
	Foreign currency translation	-310
	As of March 31, 2014	$100,929

Property_and_Equipment_net_Tab

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2014
Property and Equipment, net [Abstract]	'
Property and Equipment net	'
		31-Mar-14	31-Dec-13
	Land	$4,023	$4,152
	Buildings	9,490	10,269
	Leasehold improvements	2,795	2,789
	Office furniture and equipment	10,920	10,719
	Computer software and hardware	9,869	9,362
	Demonstration and loaned equipment	9,557	10,320
		46,654	47,611
	Accumulated depreciation and amortization	-25,124	-24,316
	Total	$21,530	$23,295

Reserve_for_Product_Warranties1

Reserve for Product Warranties (Tables)	3 Months Ended
	Mar. 31, 2014
Reserve for Product Warranties [Abstract]	'
Reserve for Product Warranties	'
		Three Months Ended March 31,
		2014	2013
	Balance, beginning of period	$3,143	$2,260
	Acquisition warranty assumed	--	191
	Warranty accrued for the period	390	656
	Repairs for the period	-522	-464
	Balance, end of period	$3,011	$2,643

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Share-Based Compensation [Abstract]	'
Share-based compensation expense	'
		Three Months Ended March 31,
		2014	2013
	Cost of revenue	$28	$59
	Marketing and sales	235	271
	Research and development	146	117
	General and administrative	1,199	913
	Total	$1,609	$1,360

Restructuring_Reserves_Tables

Restructuring Reserves (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring Reserves [Abstract]	'
Detail of activity in the restructuring reserve	'
	Balance at December 31, 2013	$	335
	Expensed		8
	Cash payments		-215
	Balance at March 31, 2014		128

Debt_and_Credit_Arrangements_T

Debt and Credit Arrangements (Tables)	3 Months Ended
	Mar. 31, 2014
Debt and Credit Arrangements [Abstract]	'
Components of long-term debt	'
		31-Mar-14	31-Dec-13
	Term loan $50 million, interest at LIBOR plus 1.75%, due September 30, 2018 with term loan principle repayable in quarterly installments of $2.5 million	$32,500	$37,500
	Term loan $2.9 million Canadian (“CAD”), interest at cost of funds plus 2.5%, due September 15, 2014 with principle repayable in monthly installments of $16,000 until August 15, 2014 and one final payment of $404,000 collateralized by a first lien on company owned land and building	437	517
	Total	32,937	38,017
	Less: current portion of long-term debt	-10,437	-10,517
	Total long-term debt	$22,500	$27,500
Maturities of long-term debt	'
	Maturities of long-term debt as of March 31, 2014 are as follows (in thousands):
	Nine months ended December 31, 2014	$		7,937
	2015			10,000
	2016			10,000
	2017			5,000
	Total Total long-term debt	$		32,937

Segment_Customer_and_Geographi1

Segment, Customer and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment, Customer and Geographic Information [Abstract]	'
Revenue and long-lived asset information by geographic region	'
		Three Months Ended March 31,
		2014	2013
	Consolidated Revenue:
	United States	$48,346	$48,364
	Foreign countries	37,278	37,470
	Totals	$85,624	$85,834
		Three Months Ended March 31,
		2014	2013
	Revenue by End Market:
	Neurology Products
	Devices and Systems	$36,116	$34,707
	Supplies	14,226	15,447
	Services	6,144	5,553
	Total Neurology Revenue	56,486	55,707
	Newborn Care Products
	Devices and Systems	14,924	17,250
	Supplies	12,276	11,464
	Services	1,938	1,413
	Total Newborn Care Revenue	29,138	30,127
	Total Revenue	$85,624	$85,834
		31-Mar-14	31-Dec-13
	Property and equipment, net:
	United States	$9,265	$9,619
	Canada	5,868	6,060
	Argentina	3,941	4,932
	Other foreign countries	2,456	2,684
	Totals	$21,530	$23,295

Business_Combinations_Details

Business Combinations (Details) (Grass Technologies [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2013
Grass Technologies [Member]	'
Unaudited Pro forma Financial Information	'
Revenue	$86,839
Income from operations	$5,239

Business_Combinations_Details_

Business Combinations (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Business Combinations (Textual) [Abstract]	'	'	'
Goodwill	$100,929,000	'	$97,238,000
Amortization of intangible assets acquired	2,061,000	1,823,000	'
Decrease in general and administrative expense related to the direct acquisition costs	12,280,000	13,966,000	'
Grass Technologies [Member]	'	'	'
Business Combinations (Textual) [Abstract]	'	'	'
Acquisition date of entity	2-Feb-13	'	'
Inventory purchase commitment	2,400,000	'	'
Purchase price paid in cash to acquire entity	21,000,000	'	'
Direct cost associated with entity acquisition	624,000	'	'
Goodwill	7,000,000	'	'
Revenue	'	86,839,000	'
Income from operations	'	5,239,000	'
Amortization of intangible assets acquired	59,300	'	'
Decrease in depreciation expense related to property and equipment acquired	14,800	'	'
Decrease in general and administrative expense related to the direct acquisition costs	624,000	'	'
Newborn Hearing Screening Services [Member]	'	'	'
Business Combinations (Textual) [Abstract]	'	'	'
Purchase price paid in cash to acquire entity	$3,600,000	'	'
Tender Touch [Member]	'	'	'
Business Combinations (Textual) [Abstract]	'	'	'
Acquisition date of entity	16-Jan-14	'	'
Hearing Health Consultants [Member]	'	'	'
Business Combinations (Textual) [Abstract]	'	'	'
Acquisition date of entity	10-Mar-14	'	'

Basic_and_Diluted_Earnings_Per1

Basic and Diluted Earnings Per Common Share (Details)	3 Months Ended
	Mar. 31, 2014
Basic and Diluted Earnings Per Common Share (Textual) [Abstract]	'
Common stock equivalents shares included in weighted average shares outstanding used to calculate diluted earnings per share	1,123,806
Common stock equivalents share options excluded in weighted average shares outstanding used to calculate diluted earnings per share	229,990

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Summary of Inventories	'	'
Raw materials and subassemblies	$21,381	$24,312
Work in process	2,053	2,584
Finished goods	19,731	17,861
Total inventories	43,165	44,757
Less: Non-current Inventories	-7,710	-7,072
Inventories, current	$35,455	$37,685

Inventories_Details_Textual

Inventories (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories (Textual) [Abstract]	'	'
Non-current Inventories	($7,710)	($7,072)

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible assets with definite lives:	'	'
Total expected amortization expense	$67,890	'
Intangible assets with indefinite lives:	'	'
Gross Carrying Amount	113,386	111,650
Accumulated Impairment	'	'
Accumulated Amortization	-45,496	-43,205
Net Book Value	67,890	68,445
Intangibles Assets, Gross Carrying Amount	146,697	145,085
Total intangible asset, Accumulated Impairment	-3,060	-3,060
Total intangible assets, Accumulated Amortization	-45,496	-43,205
Total intangibles assets	98,141	98,820
Technology [Member]	'	'
Intangible assets with definite lives:	'	'
Gross Carrying Amount	65,746	65,904
Accumulated Amortization	-26,965	-25,519
Total expected amortization expense	38,781	40,385
Customer related [Member]	'	'
Intangible assets with definite lives:	'	'
Gross Carrying Amount	32,278	31,231
Accumulated Amortization	-10,293	-9,763
Total expected amortization expense	21,985	21,468
Internally developed software [Member]	'	'
Intangible assets with definite lives:	'	'
Gross Carrying Amount	11,917	11,069
Accumulated Amortization	-5,395	-5,107
Total expected amortization expense	6,522	5,962
Patents [Member]	'	'
Intangible assets with definite lives:	'	'
Gross Carrying Amount	2,723	2,724
Accumulated Amortization	-2,121	-2,094
Total expected amortization expense	602	630
Backlog [Member]	'	'
Intangible assets with definite lives:	'	'
Gross Carrying Amount	722	722
Accumulated Amortization	-722	-722
Total expected amortization expense	'	'
Tradenames [Member]	'	'
Intangible assets with indefinite lives:	'	'
Gross Carrying Amount	33,311	33,435
Accumulated Impairment	-3,060	-3,060
Accumulated Amortization	'	'
Net Book Value	$30,251	$30,375

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Amortization expense related to intangible assets with definite lives	'	'
Total amortization	$2,061,000	$1,823,000
Technology [Member]	'	'
Amortization expense related to intangible assets with definite lives	'	'
Total amortization	1,096,000	963,000
Customer related [Member]	'	'
Amortization expense related to intangible assets with definite lives	'	'
Total amortization	647,000	601,000
Internally developed software [Member]	'	'
Amortization expense related to intangible assets with definite lives	'	'
Total amortization	288,000	239,000
Patents [Member]	'	'
Amortization expense related to intangible assets with definite lives	'	'
Total amortization	$30,000	$20,000

Intangible_Assets_Details_2

Intangible Assets (Details 2) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Expected annual amortization expense related to amortizable intangible assets	'
Nine months ending December 31, 2014	$5,965
2015	7,736
2016	6,863
2017	6,502
2018	6,236
2019	5,333
Thereafter	29,255
Total expected amortization expense	$67,890

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Technology [Member]	'
Intangible Assets (Textual) [Abstract]	'
Weighted average life of intangible assets	'15 years
Customer related [Member]	'
Intangible Assets (Textual) [Abstract]	'
Weighted average life of intangible assets	'12 years
Internally developed software [Member]	'
Intangible Assets (Textual) [Abstract]	'
Weighted average life of intangible assets	'7 years
Costs incurred for development of internal use computer software	10.4
Costs incurred for development of software to be sold	1.5
Patents [Member]	'
Intangible Assets (Textual) [Abstract]	'
Weighted average life of intangible assets	'14 years

Goodwill_Details

Goodwill (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Carrying amount of goodwill	'	'
As of December 31, 2013	'	$97,238
Acquisitions/Purchase Accounting Adjustments	4,001	'
Foreign currency translation	($310)	'

Property_and_Equipment_Net_Det

Property and Equipment, Net (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property and equipment, net	'	'
Property and Equipment, Gross	$46,654	$47,611
Accumulated depreciation and amortization	-25,124	-24,316
Total	21,530	23,295
Land [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	4,023	4,152
Buildings [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	9,490	10,269
Leasehold improvements [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	2,795	2,789
Office furniture and equipment [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	10,920	10,719
Computer software and hardware [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	9,869	9,362
Demonstration and loaned equipment [Member]	'	'
Property and equipment, net	'	'
Property and Equipment, Gross	$9,557	$10,320

Property_and_Equipment_Net_Det1

Property and Equipment, Net (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Property and Equipment, Net (Textual) [Abstract]	'	'
Depreciation and amortization expense of property and equipment	$1.20	$1.10

Reserve_for_Product_Warranties2

Reserve for Product Warranties (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Reserve for Product Warranties	'	'
Balance, beginning of period	$3,143	$2,260
Acquisition warranty assumed	'	191
Warranty accrued for the period	390	656
Repairs for the period	-522	-464
Balance, end of period	$3,011	$2,643

Reserve_for_Product_Warranties3

Reserve for Product Warranties (Details Textual)	3 Months Ended
	Mar. 31, 2014
Reserve for Product Warranties (Textual) [Abstract]	'
Product warranty period	'1 year
Extended product warranty period	'1 year

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based compensation expense	'	'
Share-based compensation expense	$1,609	$1,360
Cost of revenue [Member]	'	'
Share-based compensation expense	'	'
Share-based compensation expense	28	59
Marketing and sales [Member]	'	'
Share-based compensation expense	'	'
Share-based compensation expense	235	271
Research and development [Member]	'	'
Share-based compensation expense	'	'
Share-based compensation expense	146	117
General and administrative [Member]	'	'
Share-based compensation expense	'	'
Share-based compensation expense	$1,199	$913

ShareBased_Compensation_Detail1

Share-Based Compensation (Details Textual) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average period of recognition of unrecognized compensation expense	'2 years 9 months 18 days
Share-Based Compensation (Textual) [Abstract]	'
Number of Active Share Based Compensation Plans	2
Unrecognized compensation expense related to unvested portion of stock options	$16.50

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Contingency [Line Items]	'	'
Unrecognized Tax Benefits	$114,000	'
Effective income tax reconciliation difference, federal research and development tax credit	'	340,000
Tax positions for which it is reasonably possible that the total amount could change	585,000	'
Income Taxes (Textual) [Abstract]	'	'
Provision for income tax	$2,700,000	'
Effective tax rate	30.50%	'
United States [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Open tax examination years	'2009 through 2013	'
U.S. Federal [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Open tax examination years	'2010 through 2013	'
Significant foreign jurisdictions [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Open tax examination years	'2009 through 2013	'

Restructuring_Reserves_Details

Restructuring Reserves (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Detail of activity in the restructuring reserve	'
Beginning balance	$335
Expense	8
Cash payments	-215
Ending balance	$128

Debt_and_Credit_Arrangements_D

Debt and Credit Arrangements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Components of long-term debt	'	'
Total	$32,937	$38,017
Less current portion of long-term debt	-10,437	-10,517
Long-term debt	22,500	27,500
Term loan [Member] | Interest at LIBOR plus [Member]	'	'
Components of long-term debt	'	'
Total	32,500	37,500
Term loan [Member] | Interest at Cost of Funds Plus [Member]	'	'
Components of long-term debt	'	'
Total	$437	$517

Debt_and_Credit_Arrangements_D1

Debt and Credit Arrangements (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Maturities of long-term debt	'	'
Nine months ended December 31, 2014	$7,937	'
2015	10,000	'
2016	10,000	'
2017	5,000	'
Total	$32,937	$38,017

Debt_and_Credit_Arrangements_D2

Debt and Credit Arrangements (Details Textual)	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
	USD ($)	Revolving credit facility [Member]	Revolving credit facility [Member]	Grass acquisition [Member]	Term loan [Member]	Term loan [Member]	Term loan [Member]	Term loan [Member]	Term loan [Member]	Term loan [Member]
			USD ($)	Revolving credit facility [Member]	USD ($)	USD ($)	USD ($)	USD ($)	Interest at LIBOR plus [Member]	Interest at Cost of Funds Plus [Member]
				USD ($)					USD ($)	CAD
Debt and Credit Arrangements (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Revolving credit facility with Wells Fargo Bank	$75,000,000	'	$25,000,000	'	$50,000,000	'	'	'	'	'
Borrowing amount under credit facility	'	'	'	22,000,000	'	'	'	'	'	'
Extended term of revolving line of credit	'	'5 years	'	'	'	'	'	'	'	'
Amount of short term credit facility converted in to a term loan	'	'	'	'	'	'	31,200,000	'	'	'
Term loan outstanding	'	'	'	'	'	'	50,000,000	18,800,000	'	'
Principal amount of debt	'	'	'	'	'	'	'	'	50,000,000	2,900,000
Basis spread interest rate	'	'	'	'	'	'	'	'	1.75%	2.50%
Maturity date of debt instrument	'	'	'	'	30-Jun-17	'	'	'	30-Sep-18	15-Sep-14
Periodic principal amount	'	'	'	'	5,000,000	7,500,000	'	'	2,500,000	16,000
Final payment, collateralized by a first lien on land and building	'	'	'	'	'	'	'	'	'	404,000
Term Loan expiration period	'	'	'	'	'5 years	'	'	'	'	'

Segment_Customer_and_Geographi2

Segment, Customer and Geographic Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Consolidated Revenue:	'	'	'
Revenue	$85,624	$85,834	'
Revenue By End Market:	'	'	'
Total Revenue	85,624	85,834	'
Property and equipment, net:	'	'	'
Property and equipment, net	21,530	'	23,295
United States [Member]	'	'	'
Consolidated Revenue:	'	'	'
Revenue	48,346	48,364	'
Property and equipment, net:	'	'	'
Property and equipment, net	9,265	'	9,619
Canada [Member]	'	'	'
Property and equipment, net:	'	'	'
Property and equipment, net	5,868	'	6,060
Argentina [Member]	'	'	'
Property and equipment, net:	'	'	'
Property and equipment, net	3,941	'	4,932
Foreign Countries [Member]	'	'	'
Consolidated Revenue:	'	'	'
Revenue	37,278	37,470	'
Property and equipment, net:	'	'	'
Property and equipment, net	2,456	'	2,684
Neurology Products [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	56,486	55,707	'
Neurology Products [Member] | Devices and Systems [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	36,116	34,707	'
Neurology Products [Member] | Supplies [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	14,226	15,447	'
Neurology Products [Member] | Services [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	6,144	5,553	'
Newborn Care Products [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	29,138	30,127	'
Newborn Care Products [Member] | Devices and Systems [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	14,924	17,250	'
Newborn Care Products [Member] | Supplies [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	12,276	11,464	'
Newborn Care Products [Member] | Services [Member]	'	'	'
Revenue By End Market:	'	'	'
Total Revenue	$1,938	$1,413	'

Segment_Customer_and_Geographi3

Segment, Customer and Geographic Information (Details Textual)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Segment, Customer and Geographic Information (Textual) [Abstract	'	'
Number of Reportable Segment	1	'
Revenue [Member]	'	'
Segment, Customer and Geographic Information (Textual) [Abstract	'	'
Percentage of revenue represented by major customers	10.00%	10.00%